$GRCE

Divisadero Street Capital bought $2.17M of Lifeway Foods (LWAY) shares at $20.80-$21.09. Sonic Automotive (SAH) director Paul Rusnak acquired $1.66M in shares at $59.76. NexPoint Residential (NXRT) CIO Matt McGraner purchased $201K in stock. Grace Therapeutics (GRCE) saw $123.82K in insider buys. WILLAMETTE VALLEY VINEYARDS (WVVI) director increased holdings by $11.5K. GIC Private sold $721.6M in Medline (MDLN) shares. Apple (AAPL) exec Tim Cook sold $63.8M in stock.

Opaleye Management Inc. purchased 60,490 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at an average of $2.05 ($2.04–$2.07, $0.12M total) across 3 trades over 2026-10-01 to 2026-10-05.

Opaleye Management Inc. purchased 15,089 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at $2.10 across 2 trades over 2026-09-21 to 2026-09-23.

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On September 17, 2026, Grace Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act

Opaleye Management Inc. purchased 15,229 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at an average of $2.09 ($2.09–$2.10) across 2 trades over 2026-09-08 to 2026-09-09.

Kohli Prashant (Chief Executive Officer) purchased 100,000 shares of Grace Therapeutics, Inc. (GRCE) at $2.14 ($0.21M total) on 2026-09-09.

Grace Therapeutics (GRCE) shares rose 1.7% in pre-market trading as investors await an FDA decision on April 23 for its brain bleed drug GTx-104. The drug showed a 19% reduction in hypotension in trials and has Orphan Drug Designation, which could grant market exclusivity. Retail sentiment on Stocktwits turned neutral from bearish, with high message volumes.

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104

Grace Therapeutics (GRCE) reported a Q1 2027 net loss of $15.8M for the quarter ended June 30, 2026, versus a $3.4M loss a year earlier. Diluted EPS was $(0.91) versus $(0.21). Revenue was not reported. The company received an FDA Complete Response Letter for GTx-104, citing CMC and nonclinical items, and is pursuing an NDA resubmission.

Grace Therapeutics, Inc. (GRCE) filed a Form 10-Q for the quarter ended June 30, 2026. The filing states it recorded a $13.5M R&D impairment and extended its cash runway to 2028. The report also lists GRCE’s Nasdaq ticker (GRCE) and share count outstanding as of Aug. 11, 2026.